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Summary
Functional interactions between T and B lymphocytes are necessary for optimal activation of
an immune response . Recently, the T lymphocyte receptor CD28 was shown to bind the B7
counter-receptor on activated B lymphocytes, and subsequently to costimulate interleukin 2
production and T cell proliferation . CTLA-4 is a predicted membrane receptor from cytotoxic
T cells that is homologous to CD28 and whose gene maps to the same chromosomal band as
the gene forCD28 . It is not known, however, ifCD28 andCTLA-4 also share functional properties .
To investigate functional properties ofCTLA4, we have produced a soluble genetic fusion between
the extracellular domain of CTLA-4 and an immunoglobulin Cy chain . Here, we show that
the fusion protein encoded by this construct, CTLA4Ig, bound specifically to B7-transfected
Chinese hamster ovary cells and to lymphoblastoid cells. CTLA4Ig also immunoprecipitated
B7 from cell surface 1251-labeled extracts of these cells . The avidity of 1251-labeled B7Ig fusion
protein for immobilized CTLA4Ig was estimated (Kd -12 nM) . Finally, we show that CTLA4Ig
was a potent inhibitor ofin vitro immune responses dependent upon cellular interactions between
T and B lymphocytes . These findings provide direct evidence that, like its structuralhomologue
CD28, CTLA4 is able to bind the 137-counter-receptor on activatedB cells. Lymphocyte interactions
involving the B7 counter-receptor are functionally important for alloantigen responses in vitro .
T
he hallmark of a vertebrateimmune system is the ability
to discriminate between self and nonself. This property
has lead to the evolution of a system requiring multiple signals
to achieve optimal activation ofimmunocompetent cells (1) .
It was proposed >20 yr ago that B lymphocyte activation
requires two signals (2) . Now it is believed that all lympho-
cytes require both an antigen-specific signal, as well as a second
nonspecific one (1) .
The signals required for a Th cell antigenic response are
usually provided byAPC . The first signal is initiated by in-
teraction of the TCR complex (3) with antigen presented
in the context of class IIMHC molecules on the APC (4) .
This antigen-specific signal is not sufficient to generate a full
response, and in the absence of a second signal may lead to
clonal inactivation or anergy (5) . The requirement for a second
"costimulatory" signal provided by the APC has been demon-
strated in anumber of experimental systems (5, 6) . The mo-
lecular nature of these second signal(s) is not completely un-
derstood, although both soluble molecules, such as IL-1 (6),
and membrane-bound adhesion receptors (7) can provide
costimulatory signals in some systems.
Studies with mAbs have indicated that the homodimeric
T cell surface moleculeCD28 may also provide a costimula-
tory signal to T lymphocytes (8) . CD28 appears to function
as a regulator ofT cell-derived cytokines (9), primarily by
stabilizing their mRNAs (10), but also by regulating tran-
scription of these genes (8, 11) . Earlier studies from our lab-
oratory have shown that CD28 is a counter-receptor for the
B cell activation antigen B7 (12) . More recently, we have
characterized the interactions between CD28 and B7 using
genetic fusions ofthe extracellular portions ofB7 and CD28,
and Ig C71 chains (13) . Immobilized B7Ig fusion protein,
as well as B7+ CHO cells, costimulated T cell proliferation.
T cell stimulation with B7+ CHO cells also specifically
stimulated increased levels of 11,2 transcripts . An indication
of the role ofCD28/B7 interactions in the functional collab-
oration between Th and B lymphoid cells was provided by
the demonstration thatmAbs to bothCD28 and B7 specifically
blocked Th-mediated Ig production by B cells (14) . Addi-
tional studies by others have shown that anti-CD28 mAb
inhibited I1r2 production induced in certain T cell leukemia
cell lines by cellular interactions with aB cell leukemia line (15) :
Structurally, CD28 is a member of the Ig superfamily,
having a single extracellular V-like domain (16) . A homolo-
gous molecule, CTLA4, was identified by differential
screening of a murine cytolytic T cell cDNA library (17) .
561
￿
J . Exp. Med . ® The Rockefeller University Press " 0022-1007/91/09/0561/09 $2.00
Volume 174 September 1991 561-569Transcripts for this molecule were found in T cell popula-
tionshaving cytotoxic activity, suggesting that CTLA4 might
function in the cytolytic response (17, 18) . A gene for the
human counterpart of CTLA4 has also been cloned and
mapped (19) to the same chromosomal region (2833-34) as
CD28 (20) . Sequence comparison between human CTLA-4
and CD28 proteins revealed significant homology between
the proteins, with the greatest degree of homology being
in the juxtamembrane and cytoplasmic regions (18, 19).
The high degree ofhomology betweenCD28 andCTLA4,
together with the colocalization of their genes, raises ques-
tions as to whether these molecules are also functionally
related . However, sinceaproteinproduct ofCTLA4 has not
yet been identified, these questions remain unanswered . In
this paper, we have examined the ability of CTLA-4 to bind
the B7 counter-receptor . We have taken theapproach of con-
structingagenetic fusion encoding CTLA4Ig, a solublemol-
eculecomprising the extracellular domain ofCTLA-4joined
to an Ig Cy1 chain. We have studiedbinding properties of
CTLA 4Ig and have determined its functional effects on in
vitro T and B lymphocyte responses.
Materials and Methods
mAbs and Ig Fusion Proteins.
￿
Murine mAbs 9.3 (anti-CD28)
and G19-4(anti-CD3), G3-7 (anti-CD7), BB-1 (anti-B7 antigen),
and ratmAb 187.1 (anti-mouse tc chain) have been described previ-
ously (21-23), and were purified from ascites before use . The hy-
bridoma producing mAb OKT8 was purchased from the Amer-
ican Type Culture Collection (Rockville, MD) and the mAb was
also purified from ascites before use. mAb 4G9 (anti-CD19) was
generously provided by Dr. E. Engleman (Stanford University) .
Purified human-mouse chimeric mAb L6 (havinghuman Cyl Fc
portion) was a gift of Margit Gayle and Dr. Perry Fell (Oncogen,
Seattle, WA). Receptor Ig Cy fusion proteins B7Ig, CD5Ig, and
CD28Ig were prepared as previously described (13) .
Cell Culture and Transfections.
￿
COScells were transfected with
expression plasmids as described (13) . Ig fusion proteins were purified
from serum-free conditionedmedium from transfectedCOS cells
by protein A affinity chromatography (13) . 137' CHO and
CD28' CHO have been previously described (13) . CD7' CHO
cells were isolated by cotransfection and amplification of an ex-
pressibleCD7cDNA clone (24) as described (12) .CHO transfec-
tants were maintained in DMEM supplemented with 10% FCS,
0.2 mM proline, and 1 AM methotrexate . TheEBVtransformed
lymphoblastoid cell lines (LCL),' PM and T51, were maintained
in RPMI 1640 supplemented with 10% FCS .
Polymerase Chain Reaction .
￿
DNAfragments were amplified by
PCR(25), usingprimer pairs describedbelow. PCRreactions (0 .1
ml final volume) were run in Taq polymerase buffer (Stratagene,
Torrey Pines, CA), containing 20 Amol each dNTP ; 50-100 pmol
of the indicated primers; template (1 ng plasmid orcDNA synthe-
sized from<1Ag totalRNAusingrandom hexamer primer ; refer-
ence 26) ; and Taqpolymerase (Stratagene) . Reactions were runon
a thermocycler (Perkin Elmer-Cetus) for 16-30 cycles (a typical cycle
consisted of steps of 1 min at 94°C, 1-2 min at 50°C, and 1-3
min at 72°C) .
Plasmid Construction.
￿
cDNAsencoding CD7(24),CD28 (16),
' Abbreviation used in this paper. LCL, lymphoblastoid cell lines.
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and B7 (27) have been described previously. Construction of
OMCD28, a CD28 cDNA modified for more efficient expression
by replacing the signal peptide with the analogous region from
oncostatinM (28), and theB7Ig and CD28Ig expression plasmids
have also been described (13) .
A genetic fusion encoding CTLA4Ig construct was made es-
sentially as described previously for the CD28Ig construct (13) .
The extracellular domain o£ CTLA4 was cloned by PCR using
synthetic oligonucleotides corresponding to the published sequence
(19) . Since a signal peptide for CTLA-4 was not identified in the
CTLA-4 gene, the NHz terminus of the predicted sequence of
CTLA-4 was fused to the signal peptide of oncostatinM (28) in
two steps using overlapping oligonucleotides . For the first step,
the oligonucleotideCTCAGTCTGGTCCTTGCACTCCTGTTT
CCAAGCATGGCGAGCATGGCAATGCACGTGGCCCAGCC
(which corresponded to theCOOH-terminal 15 amino acidsfrom
the oncostatinM signal peptide fused to the NHz-terminal seven
amino acids of CTLA-4) was used as forward primer, andTTT
GGGCTCCTGATCAGAATCTGGGCACGGTTC (correspond-
ing to residues 119-125 of CTLA-4 and containing a Bc1I restric-
tion enzyme site) as reverse primer. The template for this step was
cDNA synthesized from total RNA from H38 cells (an HTLV II-
infected T cell leukemic cell line kindly provided by Drs. Z. Sala-
hudin andR. Gallo, National Cancer Institute) . A portion of the
PCRproductfrom the first step was reamplified, using an overlap-
ping forward primer, corresponding to the NHz-terminal por-
tion of the oncostatinM signal peptide and containing a HindIII
restriction endonuclease site, CTAGCCACTGAAGCTTCACCA-
ATGGGTGTACTGCTCACACAGAGGACGCTGCTCAGTCTG-
GTCCTTGCACTC and the same reverse primer. The product of
this PCRreaction was digested with HindIII and BcII and ligated
together with a BclI/XbaI-cleavedcDNA fragment encoding the
hinge, CH2, and CH3 regions of Ig Cyl (13) into the HindIII/
XbaI-cleaved expression vector CDM8 (Invitrogen, San Diego,
CA) .
The sequence ofthe resulting CTLA4Ig fusion was determined
and found to correspond exactly to the published sequence of
CTLA-4, except that thecodon for amino acid 111 was determined
to be ACC rather than GCC as originally published (19) ; this
difference was also confirmed on an independent clone spanning
this region . The result of this difference is that the codon for
amino acid 111 specifies threonine rather than alanine, as previ-
ously described .
To reconstruct full-length human CTLA-4, acDNA fragment
encoding thetransmembrane andcytoplasmic domainswascloned
byPCRandthenjoined with afragment fromCTLA4Igencoding
the oncostatin M signal peptide fused to the NHz terminus of
CTLA-4 . For this purpose, the oligonucleotide GCAATGCAC-
GTGGCCCAGCCTGCTGTGGTACTG (corresponding to the first
11 amino acids in the predicted coding sequence) was used as a
forward primer, and TGATGTAACATGTCTAGATCAATTGAT
GGGAATAAAATAAGGCTG (corresponding to the last eight
amino acids in CTLA4 and containing an XbaI site) as reverse
primer. Template again was cDNA synthesized from H38 cells .
Products of the PCR reaction were cleaved with the restriction
endonucleases Ncol and XbaI, and the resulting 316-bp product
was gel purified . A -340-bp HindIII/Ncol fragment from the
CTLAIg fusion described above was also gel purified, and both
restriction fragments were ligated into HindIII/Xba-I cleaved
CDM8 . The resulting construct encoded full-lengthCTLA4 and
is designated OMCTLA4 . CTLA-4 encoded by this construct also
contained threonine at position 111, rather than alanine as reported
previously (19) .Ligation products were transformed into MC1061/p3 cells and
colonies were screened for the appropriate plasmids . Sequences of
the resulting constructs were confirmed by DNA sequence anal-
ysis using a commercial kit (United States Biochemical Corp., Cleve-
land, Ohio).
Immunostaining andFACS®Analysis.
￿
Transfected cells or LCL
were analyzed by indirect immunostaining. Before staining, COS
andCHO cells were removed from their culture vessels by incuba-
tion in PBS containing 10mM EDTA. Cells were first incubated
withmAbs or Ig fusion proteins at 10 hg/ml inDMEM containing
10% FCS for 1-2 h at 4°C . Cells were then washed and incubated
for an additional 0.5-2 h at 4°C with FITC-conjugated goat
anti-mouse Ig or with FITC-conjugated goat anti-human IgCy
serum (both from Tago Corp., Burlingame, CA) . When binding
of both mAbs and Ig fusion proteins was measured in the same
experiment, FITC-conjugated anti-mouse and anti-human second
step reagents were mixed together before use. Fluorescence on a
total of 10,000 cells was then analyzed by FACS® (Becton Dick-
inson & Co ., Mountain View, CA) .
PBL Separation and Stimulation .
￿
PBL were isolated by centrifu-
gation through Lymphocyte SeparationMedium (Litton Bionetics,
Kensington, MD) . Alloreactive T cells were isolated by stimula-
tion ofPBL in a primary MLR. PBL were cultured at 106/ml in
RPMI 1640 supplemented with 10% FCS in the presence of 0.25
x 106/ml irradiated (5,000 rad) T51 LCL . After 6 d, alloreactive
"blasts" were cryopreserved. Secondary MLR were conducted by
culturing thawed alloreactive blasts together with fresh irradiated
T51 LCL in the presence and absence ofmAbs and Ig fusion pro-
teins. Cells were cultured in 96-well flat-bottomed plates (4 x 104
alloreactive blasts and 104 irradiated T51 LCL cells/well) in a
volume of 0.2 ml ofRPMI 1640 containing 10% FCS. Cellular
proliferation of quadruplicate cultures was measured by uptake of
[3H]thymidine during the last 6 h of a 2-3-d culture.
CD4 * T cells were isolated from PBL as described (29) . B cells
were purified by positive selection from peripheral blood by pan-
ning (30) with anti-CD19 mAb 4G9 . To measure Th-induced Ig
production, 106 CD4* T cells were mixed with 106 allogeneic
CD19+ B cells in 1 ml ofRPMI 1640 containing 10% FCS. After
culture for 6 d at 37°C, production ofhuman IgM was measured
in the culture supernatants as described (14) .
Binding Assays.
￿
B71g was labeled with "1I to a specific activity
of -2 x 106 cpm/pmol. 96-well plastic dishes were coated for
16-24 h with a solution containingCTLA4Ig (0.5 lAg in a volume
of0.05 ml of10mM Tris, pH 8). Wells were blocked with binding
buffer (DMEM containing 50mM BES [Sigma Chemical Co .],
pH 6.8, 0.1% BSA, and 10% FCS) before addition of a solution
(0.09 ml) containing 's1I-B7Ig (-5 x 101 cpm) in the presence
or absence ofcompetitor. After incubation for 2-3 h at 23°C, wells
were washed once with binding buffer and four times with PBS.
Bound radioactivity was then solubilized by addition of 0.5 N
NaOH, and quantified by gamma counting.
Results
Construction ofa Soluble CTLA-41gCy Fusion Protein .
￿
We
previously have shown that CD28Ig, the soluble product of
a genetic fusion between the extracellular domain ofCD28
and an IgCyl domain, bound the B7 counter-receptor (13) .
To determine whether CTLA4 also bound B7,we constructed
an analogous genetic fusion between the extracellular domain
of CTLA-4 and an Ig Cy1 domain (Fig. 1 A).
Since the expression ofCTLA4 in human lymphoid cells
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has not been reported, it was necessary to first find a source
ofCTLA-4 mRNA . We therefore screened byPCR cDNA
made from total cellular RNA of different human leukemia
cell lines using as primers oligonucleotides derived from the
published sequence of the CTLA-4 gene (19) . Ofthe cDNAs
tested, H38 cells (anHTLV 11-associated leukemia line) gave
the best yield ofPCR products having the expected size . A
cDNA containing the predicted coding sequence of the ex-
tracellular domain ofCTLA-4 was then assembled from two
PCR fragments amplified from H38cDNA, as described in
Materials and Methods . This fragment was digested with ap-
propriate restriction enzymes and ligated together with a
cDNA encoding the hinge, CH2, andCH3 domains ofhuman
Ig Cy1, into themammalian expression vector, CDM8 . Sev-
eral isolates were transfected into COS cells, and superna-
tants were tested by indirect immunofluorescence and FACS®
analysis for the presence of proteins that bound to B7'
CHO cells . Preliminary experiments indicated that several
isolates encoded proteins that bound to B7+ CHO cells (see
below) . TheDNA sequence of one such isolate was then de-
termined and found to encode CTLA4Ig, as shown in Fig.
1 A . CTLA4Ig contained a single base pair difference with
the published sequence ofCTLA-4 (19), such that an alanine
residue at position 111 was changed to threonine. Threonine
is also present at this position in the aligned sequences of
murineCTLA-4 (17), murineCD28 (30), and human CD28
(16, 31) .
CTLA4Ig was purified by protein A chromatography from
serum-freeculture supernatants oftransfectedCOS cells (Fig.
1 B) . Under nonreducing conditions CTLA4Ig migrated as
a MI -100,000 species, and as a M, -50,000 species under
reducing conditions (Fig . 1 B). CTLA4Ig therefore behaves
during SDS-PAGE as a disulfide-linked dimer. Since the Ig
Cy hinge disulfides were eliminated during construction, a
native disulfide linkage in CTLA4 is most likely involved
in this bond formation . CD28Ig also behaves as a disulfide-
linked dimer during SDS-PAGE (13) .
Binding Activity ofCTLA4Ig .
￿
The binding activities of
purified CTLA4Ig and CD28Ig (13) on B7+ CHO cells and
on a lymphoblastoid cell line (PM LCL) were compared in
the experiment shown in Fig . 2 . TransfectedCHO cell lines
and PMLCL were incubated with equivalent concentrations
(10 Ag/ml) of CD51g, CD28Ig, or CTLA4Ig, and binding
was detected byFACS® after addition of an FITC-conjugated
second-step reagent . CD28Ig bound weakly but significantly
to B7+ CHO cells and not at all to PM LCL . The B7+
CHO cells used in this experiment expressed lower amounts
ofB7 than those used in previous experiments (13) and bound
correspondingly lower levels of CD28Ig. CTLA4Ig bound
more strongly to both cell lines than CD28Ig. The differ-
ence between CD28Ig and CTLA4Ig binding to B7+ CHO
cells was maintainedwhen concentrations of the fusion pro-
teins were titrated (data not shown) . Neither CD28Ig nor
CTLA4Ig bound to control CD28+ CHO cells .
To test whether CTLA4 expressed on the cell surfacemem-
brane bound the B7 antigen, we cloned by PCR a cDNA
(OMCTLA4) encoding full-length mature human CTLA-4
fused to the oncostatin M signal peptide (see Materials andFigure 1 .
￿
Construction and expression of CTLA4Ig. (A) Map of CTLA4Ig constructs . A cDNA construct encoding the indicated portions of on-
costatinM (dark shaded regions), CTLA-4 (unshaded regions), and human Ig Cyl (stippled regions) was constructed as described in Materials and Methods.
Sequences displayed show the junctions between CTLA-4 (capital letters), and the signal peptide (SP) of oncostatin M, and the hinge (H) of Ig C-yl.
The amino acid in parentheses was introduced during construction . Asterisks denote cysteine to serine mutations introduced in the Ig Cy hinge region.
The Ig superfamilyV-like domain present in CTLA-4 is indicated, as are the CH2 and CH3 domains of Ig Cy1. (B) Purification of CTLA4Ig. An
expression plasmidconstruct encoding CTLA4Ig was transfected intoCOS cells, and Ig Cy-containing proteins were purified from serum-free-conditioned
medium . Concentrations of CTLA4Ig were determined assuming an extinction coefficient at 280 nm of 1 .6 (experimentally determined by amino
acid analysis of a solution of known absorbance) . Molecular weight standards (lanes 1 and 3) and samples (1 p,g) of CTLA4Ig (lanes 2 and 4) were
subjectedto SDS-PAGE (4-12% acrylamide gradient) under nonreducing
￿
lanes 1 and 2) or reducing (+WE, lanes 3 and 4) conditions . Proteins
were visualized by staining with Coomassie brilliant blue.
Methods). COS cells were transfected with expression plasmids
CD7, OMCD28, andOMCTLA4, and 48 h later, cells were
tested for expression of the appropriate cell surface markers
by FRCS® analysis (data not shown) . The B7Ig fusion pro-
tein (but not control CD5Ig fusion protein) bound to both
CD28- and CTLA4 transfected cells. mAb 9.3 bound to
CD28-transfected COS cells, but not to CTLA4-transfected
cells. CD7-transfectedCOS cellsbound neithermAb 9.3 nor
No Addition
CD5 Ig
CD28Ig
CTLA4Ig
CD28+CHO
￿
B7+ CHO
￿
PM LCL
Figure 2 .
￿
CTLA4Ig binds specifically to cells that express the B7 an-
tigen . Amplified transfectedCHO cells expressing CD28 or B7, andPM
LCL cells were incubated with medium only (no addition), or human Ig
Cyl-containing proteins CD5Ig, CD28Ig, or CTLA4Ig, followedby FITC-
conjugated goat anti-human Ig second-step reagents. A total of 10,000
stained cells was then analyzed by FRCS®.
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either ofthe fusion proteins. Thus, membrane-boundCTLA4
and solubleCTLA4 Ig bothbound the B7 counter-receptor.
We measured the apparent avidity of interaction between
CTLA4Ig and B7Ig using a solid phase binding assay. B7Ig
was radiolabeled with 1251, and bound to immobilized
CTLA4Ig in the presence or absence of increasing concen-
trations of various competitors (Fig. 3 A) . Only anti-B7 mAb
BB-1 and unlabeled B7Ig competed significantly for 125I-
B7Ig binding (half-maximal effects at -175 and -22 nM,
respectively) . The slope ofthe inhibition curve for mAb BB-1
was different than the slope of the curve for B7Ig, and does
not appear to reach the same maximal inhibition . The ineffi-
ciency of mAb BB-1 (an IgM mAb) at 1251-B7Ig binding
competition was also observed in other experiments andmay
indicate that the mAb has lower affinity for B7Ig or that
the BB-1 epitope does not exactly coincide with the binding
site for CTLA4Ig . Neither chimeric mAb L6 (a nonbinding
control Ig molecule), nor anti-CD28 mAb 9.3 competed effec-
tively, although the highest concentration ofmAb 9.3 used
was sufficient to inhibit binding 1251-B7Ig to immobilized
CD28Ig or to cell surface expressed CD28 by r90% (13) .
The competition data from Fig. 3 A were plotted in the
Scatchard representation, and a Kd -12 nM was calculated
for binding of 1251-B7 to immobilized CTLA4Ig (Fig. 3 B) .
Immunoprecipitation Analysis ofCell Surface Proteins Binding
CTLA4Ig . We next compared by immunoprecipitation anal-
ysis the abilities of CD28Ig, CTLA4Ig, and CD5Ig to bind
solubilized B7 from 1251-surface labeled cells. As shown in
Fig . 4, a diffusely migrating (Mr -50,000-75,000 ; center at
-60,000) radiolabeled protein was immunoprecipitated byB 0.075
u-
`m
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0
0
￿
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Figure 3 .
￿
12 51-labeled B7Ig binds with high avidity to immobilized
CTLA4IG . (A) Competition binding analysis of 1251-B7Ig . 96-well plastic
dishes were coated with CTLA4Ig as described in Materials and Methods.
1251-labeled B7Ig (5 x 10 5 cpm, 2 x 106 cpm/pmol) was then added to
a concentration of 4 nM in the presence of the indicated concentrations
ofunlabeled chimericmAb L6, mAb 9 .3,mAb BB-1, or B7Ig. Plate-bound
radioactivity was determined and is expressed as a percentage of radioac-
tivitybound to wells treated without competitor (28,300 cpm) . Each point
represents the mean oftriplicate determinations; replicates varied from the
mean by 420%. Concentrations were calculated based on a M, of 75,000
per binding sitefor mAbs and 51,000per binding site for B7Ig. (B) Scatchard
analysis of 125Ig binding to immobilized CTLA4Ig . Data from the unla-
beled B7Ig competition binding experiment shown inA were replotted
in the Scatchard representation and a binding constant (Ka) was estimated
from the slope ofthe line best fitting the experimental data (r = -0.963).
CTLA4Ig from B7+ CHO cell extracts . On longer ex-
posure, a protein of this size was also visible in samples im-
munoprecipitated with CD28Ig, but not CD5Ig. In another
experiment, this protein was again precipitated byCTLA4Ig
from B7+ CHO cells, but not from surface-labeled 125J_
labeled CD28+ CHO cells (data not shown) . CTLA4Ig,
but not CD28Ig or CD5Ig, also immunoprecipitated a mol-
ecule of the same size from extracts of 1251-labeled lympho-
blastoid cells.
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Figure 4 .
￿
Immunoprecipitation ofB7 from transfectedCHO and lym-
phoblastoid cell lines by CTLA4Ig . B7+ CHO and PM lymphoblastoid
cells were surface labeled with 1251, and extracted with a nonionic deter-
gent solution (13). Aliquots containing -1 .5 x 10 1 cpm were subjected
to immunoprecipitation analysis (13) with no addition, or 2 Ftg each of
CD28Ig, CTLA4Ig, or CD5Ig . Washed immunoprecipitates were then
analyzed by SDS-PAGE (10-20% acrylamide) under reducing conditions.
The gel was then dried and exposed to X-ray film for 1 d (left) or 10 d
(center and right) .
CTLA4Ig Is a Potent Inhibitor ofImmune Responses In
Vitm Previous studies showed that anti-CD28 mAb, 9.3,
and anti-B7 mAb, BB-1, inhibited proliferation of alloantigen
specific Th cells, as well as Ig secretion by alloantigen-
presentingB cells (14, 32-34) . These observations suggested
that soluble forms ofCD28, CTLA-4, or B7 might also in-
hibit these responses . The effects of CD28Ig, CTLA4Ig, and
B7Ig on T cell proliferation in anMLR were compared in
the experiment shown in Fig. 5 . CTLA4Ig inhibited theMLR
reaction in a dose-dependent fashion by amaximum of790%,
with half-maximal response at -30 ng/ml (-0.8 nM) . The
Fab fragment ofmAb 9.3, a more potent inhibitor ofMLR
than whole mAb 9.3 (32), was also inhibitory, but at much
higher concentrations (ti800 ng/ml or -30 nM for half-
maximal response) . B7Ig and CD28Ig did not significantly
inhibit theMLR even at higher concentrations. In other ex-
periments, addition ofB71g together with CTLA4Ig reversed
the inhibition ofMLR by CTLA4Ig, indicating that the in-
hibition was specifically due to interactions with B7 (data
not shown) .
The effects ofCTLA4Ig on Th induced Ig secretion was
also examined (Fig. 6) . CD4+ T cells stimulated IgM
production by allogeneic CD19+ B cells . In the absence of
CD4+ T cells, IgM levels were only ti7% of levels mea-
sured in the presence ofCD4+ T cells. As shown previously
(14), mAbs 9.3 and BB-1 significantly inhibited Th-induced
IgM production (63% and 65% inhibition, respectively) .
CTLA4Ig was evenmore effective as an inhibitor (89% inhi-
bition) than were these mAbs . Inhibition by control Ig mol-
ecules, mAbs OKT8 and CD5Ig, was much less. None ofc
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Figure 5 .
￿
CTLA4Ig inhibitsTcell proliferation in a mixed lymphocyte
reaction . PrimaryMLR blasts were stimulated with irradiated T51 LCL
in the absence or presence ofthe indicated concentrations of murinemAb
9 .3 Fab fragments, or B7Ig, CD28Ig, or CTLA4Ig IgCy fusion proteins.
Cellular proliferation was measured by [ 3H)thymidine incorporation after
4 d and is expressed as the percentage of incorporation by untreated cul-
tures (21,000 cpm) . Shown are the means ofquadruplicate determinations
(SEM <10%) .
these molecules significantly inhibited Ig production mea-
sured in the presence of Staphylococcus aureus entorotoxin B
(data not shown) . Similar results were obtained with CD4+
T cells and B cells derived from other donors.
Discussion
Previous studies showed that CTLA-4 and CD28 form a
subgroup of closely related molecules belonging to the Ig
superfamily (35) . Herewe have shown thatCTLA4 andCD28
are functionally as well as structurally related . Soluble
CTLA4Ig bound specifically to the surface of B7 + CHO
cells and to aLCL (Fig. 2) . CTLA4Ig also specificallyimmu-
noprecipitated identically sized proteins from extracts of these
cells (Fig. 4), indicating that CTLA4Ig retained binding ac-
tivity for solubilized B7 . Finally, the Kd of binding of
soluble 1251-B7Ig for immobilized CTLA4Ig was estimated
as ru12 nM (Fig. 3 B) . This apparent Kd compares favorably
with higher affinity mAbs (Kd 2-10,000 nM ; reference 36)
and is similar to or greater than Kd values of integrin
receptors and their ligands (10-2,000 nM ; references 37-39) ;
the binding of soluble alloantigen to the TCR of a murine
T cell hybridoma (N100 nM ; reference 40) ; interactions be-
tween CD2 and LFA3 (400 nM ; reference 41) ; and interac-
tions between CD4 andMHC class II molecules (42) . Taken
together, these observations indicate thatCTLA4 is a receptor
for the B cell activation antigen, B7 . Thus, both CD28 and
CTLA-4 bind the same counter-receptor .
Side-by-side comparisons were made of the abilities of
CD28Ig and CTLA4Ig to directly bind tomembranebound
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Figure 6.
￿
CTLA4Ig inhibits helper T cell-induced Ig production by
human B cells. CD4' T cells were mixed with allogeneic CD19' B cells
in the presence or absence of the indicated Ig molecules as described in
Materials and Methods . Murine mAbs OKT8, 9.3, and BB-1 were added
at 20 ug/ml, and Ig fusion proteins, at 10 ug/ml . After 6 d of culture,
concentrations of human IgM (SEM <5%) in culture supernatants were
determined as described (14). IgM production by B cells cultured in the
absence of CD4' T cells was 11 ng/ml .
B7 (Fig . 2), to immunoprecipitate B7 solubilized from different
cell types (Fig . 4), and to inhibit T cell proliferation in an
MLR (Fig. 5) . In all cases, CTL4Ig was more effective than
CD28Ig . We have also found that CTL4Ig is a much more
effective competitor for binding of biotinylated CTLA4Ig
to B7+ CHO cells than is CD28Ig (data not shown) . The
avidity of soluble 1151-labeled B7Ig for immobilized
CTLA4Ig (Kd -12 nM) was also found to be -20-fold
greater than its avidity under identical conditions for immobi-
lized CD28Ig (Kd -200 nM ; reference 13) . A preponder-
ance ofevidence suggests, therefore, thatCTLA4Ig has higher
avidity for B7 than does CD28Ig .
There are several possible explanations for this finding. First,
it is possible that the Ig fusion proteins do not accurately
reflect native interactions between membrane-boundCTLA4,
CD28, and the B7 counter-receptor . Perhaps the low relative
avidity ofCD28Ig indicates that this protein does not retain
full binding activity. We feel this possibility is unlikely since
in previous studies the avidities of 1251-B7Ig for immobilized
CD28Ig andCD28Ig expressed on the membrane of transfected
cells were found to be identical (13) . We did not measure
avidity between 1251-B7Ig and membrane-bound CTLA4 in
the present study, so we do not know if CTLA4Ig likewise
retains most of the binding activity of membrane-bound
CTLA-4 . However, the high Kd of interaction between
CTLA4Ig and B7Ig argues in favor of this being the case.
It is also possible that the high apparentKd ofCTLA4Ig
is the result ofgreater valency of this fusion protein . CTLA4Ig
forms a disulfide-linked dimer ofM r "50,000 subunits (Fig .
1 B) . Since no interchain disulfides would be predicted to
form in the Ig portion of this fusion, it seems likely thatcysteines from CTLA4 are involved in disulfide bond forma-
tion. The analogous CD28Ig fusion protein (13) also con-
tains interchain disulfide linkage(s). The sizes in solution of
CTLA4Ig and CD28Ig were also compared by size fraction-
ation on a TSK G3000SW column eluted with PBS. CTLA4Ig
eluted with an apparent Mr of -200,000, while CD28Ig
eluted with an apparent Mr of -300,000. Both CTLA4Ig
and CD28Ig behave in solution as molecules approximately
twice as large as their apparent Mrs determined by SDS-
PAGE (reference 13; and Fig. 2), suggesting that they form
higher aggregates, possibly tetramers. It is not known how
many binding sites for B7 these molecules contain, but the
difference in apparent avidities of CD28Ig and CTLA4Ig is
not easily explainable by differences in their size or degree
of aggregation in solution.
Finally, it is possible that the greater apparent avidity of
CTLA4Ig indicates that CTLA4 is a higher avidity receptor
for B7. Proof of this point will require studies comparing
the affinities of membrane-bound CD28 and CTLA4 for
soluble and membrane-bound B7. These studies are techni-
cally difficult at the present time. The OMCTLA4 cDNA
clone is expressed poorly in COS and CHO cells (Linsley,
P.S., unpublished observations), making binding measure-
ments to CTLA4-transfected cellsmore difficult. Likewise,
since we previously showed by binding inhibition and im-
munoprecipitation experiments that CD28 was the major B7Ig
binding protein from activated PBL (13), the levels of ex-
pression of native CTLA-4 in activated PBL are likely to be
less than levels of CD28. This is consistent with preliminary
results from RNA blotting experiments showing that CTLA4
transcripts are more generally present at lower levels in cell
lines and in PBL than CD28 transcripts (Urnes, M., and P.S.
Linsley, unpublished observation) . These findings may indi-
cate that CTLA-4 is a receptor of low abundance, but high
avidity.
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We thank Mark Stebbins for help in characterization of Ig fusion proteins: Virginia Smith for amino
acid analyses; Derek Hewgill for help with the FRCS®; Christine Eberhardt and Monica Van der Vieren
for technical assistance; Dr. Alejandro Aruffo for stimulating discussions and a critical review ofthe manu-
script; and Drs. Karl Erik and Ingegerd Hellstrom for continued support and encouragement.
Address correspondence to PeterS. Linsley, Oncogen Division, Bristol-Myers Squibb Research Institute,
3005 First Avenue, Seattle, WA 98121.
Received for publication 13 February 1991 and in revised form 13 May 1991.
1 . Janeway, C.A. 1989. Approaching the asymptote? Evolution
and revolution in immunology. ColdSpring Harbor Symp Quant.
Biol. 54:1.
2. Bretscher, P., and M. Cohn. 1970. A theory of self-nonself
discrimination. Science (Wash. DC). 169:1042.
3. Weiss, A. 1990. Structure and function of the T cell antigen
567
￿
Linsley et al.
receptor. J. Clin. Invest. 86:1015.
4. Allen, P.M. 1987. Antigen processing at the molecular level.
Immunol Today . 8:270.
5. Schwartz, R.H. 1990. A cell culture modelfor T lymphocyte
clonal anergy. Science (Wash. DC). 248:1349.
6. Weaver, CT, and E.R. Enanue. 1990. The costimulatory func-tion of antigen-presenting cells . Immunol . Today. 11:49 .
7 . Springer,T.A . 1990 . Adhesion receptors of theimmune system .
Nature (Lon4 346:425 .
8 . June,C.H ., J.A . Ledbetter, P.S . Linsley, andC.B. Thompson .
1989 . Role of theCD28 receptor in Tcell activation . Immunol .
Today. 11:211 .
9 . Thompson, C.B ., T Lindsten, J.A . Ledbetter, S.L . Kunkel,
H.A . Young, S.G. Emerson,J.M. Leiden, andC.H . June. 1989 .
CD28 activation pathway regulates the production ofmultiple
T cell-derived lymphokines/cytokines . Proc Natl. Acad. Sci.
USA . 86:1333 .
10 . Lindsten, T, C.H . June, J.A . Ledbetter, G. Stella, andC.B.
Thompson . 1989 . Regulation oflymphokine messengerRNA
stability by a surface-mediatedT cell activation pathway. Science
(Wash. DC). 244:339 .
11 . Fraser, J.D., B.A . Irving,G.R . Crabtree, andA. Weiss. 1991 .
Regulation of interleukin-2 gene enhancer activity by theT
cell accessory molecule CD28 . Science (Wash . DC) . 251:313 .
12 . Linsley, P.S., E.A . Clark, andJ.A . Ledbetter. 1990 . TheT cell
antigen. CD28, mediates adhesion withB cellsby interacting
with the activation antigen, B7/BB-1 . Proc . Natl. Acad. Sci.
USA . 87:5031 .
13 . Linsley, P.S.,W Brady, L. Grosmaire, A. Aruffo, N.K. Da-
mile, and J.A. Ledbetter. 1991 . Bindingof theB cell activation
antigenB7 to CD28 costimulates T cell proliferation and in-
terleukin 2 mRNA accumulation.J . Exp. Med . 173:721 .
14 . Damle, N.K ., P.S. Linsley, and J.A. Ledbetter. 1991 . Direct
helperTcell-induced B-cell differentiation involves interaction
between Tcell antigenCD28 and B-cell activation antigen B7 .
Eur . J. Immunol. 21:1277 .
15 . Kohno, K ., Y Shibata, Y . Matsuo, andJ . Minowada . 1990.
CD28 molecule as a receptor-like function for accessory signals
in cell-mediated augmentation of II72 production . Cell Immunol .
131:1 .
16 . Aruffo,A ., andB . Seed . 1987 . Molecular cloning of a CD28
cDNA by a high-efficiency COS cell expression system . Proc.
Natl. Acad. Sci. USA . 84:8573 .
17 . Brunet, J.-F., F . Denizot, M.-F . Luciani, M. Roux-Dosseto,
M. Suzan,M.-G . Mattei, andP . Golstein. 1987.Anew member
of the immunoglobulin superfamily-CTLA-4 . Nature (Lond.).
328:267 .
18 . Brunet,J.-F., F. Denzoit, andP . Golstein . 1988 . A differential
molecularbiology approach for genes preferentially expressed
in functionalTlymphocytes : the CTLA genes . Immunol . Rev .
103:21.
19 . Dariavach, P ., M.-G. Mattei, P . Golstein, andM.-P. Lefranc.
1988 . Human Ig superfamilyCTLA-4 gene : chromosomal lo-
calization and identity of protein sequence between murine
and human CTLA-4 cytoplasmic domains . Eur.J. Immunol .
18:1901 .
20 . Lefage-Pochitaloff, M.,R. Costello,D . Couez, J . Simonetti,
P . Mannoni, C. Mawas, andD. Olive. 1990. Human CD28
andCTLA-4 Ig superfamily genes arelocated on chromosome
2 at bands 933-934 . Immunogenetics. 31:198 .
21 . Ledbetter, J.A ., C.H . June, L.S. Grosmaire, and P.S. Rabino-
vich . 1987 . Crosslinking of surface antigens causes mobiliza-
tion of intracellular ionized calcium in T lymphocytes. Proc .
Nad . Acad. Sci. USA . 84:1384 .
22 . Ledbetter, J.A., J.B. Imboden, G.L . Schieven, L.S. Grosmaire,
P .S . Rabinovitch, T Lindsten,C.B.Thompson,andC.H .June.
1990. CD28 ligation in Tcell activation : evidence for two signal
transduction pathways . Blood. 75:1531 .
568
￿
CTLA4 Binds the B7 Antigen
23 . Yokochi, T., R.D. Holly, and E.A . Clark . 1981. B lympho-
blast antigen (BB-1) expressed on Epstein-Barr virus activated
B cell blasts, B lymphoblastoid cell lines, and Burkitt's lym-
phomas . J. Immunol . 128:823 .
24 . Aruffo, A., andR. Seed. 1987 . Molecularcloningof twoCD7
(T-cell leukemia antigen) cDNAs by a COS cell expression
system. EMBO (Eur . Mol. Biol. Organ) J. 6:3313 .
25 . Saiki, R.K ., F . Scharf, F. Faloona, K.B. Mullis, G.T. Horn,
H.A . Erlicj, andN. Arnheim . 1985 . Enzymatic amplification
of,fi-globin genomicsequences and restriction site analysis for
diagnosis of sickle cell anemia . Science (Wash . DC) . 230:1350 .
26 . Kawasaki, E.S. 1990 . Amplification ofRNA, inPCRProtocols.
M.A . Innis,D.H . Gelfand, Jj. Sninsky, and T.J . White, editors.
Academic Press, San Diego, CA . 21-27.
27 . Freeman, G.J ., A.S . Freedman, J.M . Segil, G. Lee, J.F.
Whitman, and L.M . Nadler. 1989 . B7, anew member of the
Ig superfamily with unique expression on activated and neo-
plasticB cells . J. Immunol . 143:2714 .
28 . Malik, N., J.C. Kallestad, N.L . Gunderson, S . Austin, M.G .
Neubauer,V Ochs, H. Marquardt, J.M . Zarling, M . Shoyab,
C.M . Wei, P.S. Linsley, and TM . Rose . 1989 . Molecular
cloning, sequence analysis, and functional expression of the
growth regulator, oncostatin M. Mol . Cell. Biol. 9:2847 .
29 . Damle, N.K ., and A. Aruffo. 1991 . Vascular cell adhesion
molecule-1 (VCAM-1) induces Tcell antigen receptor-
dependent activation of CD4` T lymphocytes. Proc. Natl.
Acad. Sci. USA . In press.
30 . Gross, J.A ., T . St . John, andJ.P. Allison . 1990 . The murine
homologue of theT lymphocyte antigen CD28 . Molecular
cloning and cell surface expression .J . Immunol . 144:3201 .
31 . Lee,K.P., C. Taylor, B . Petryniak, L.A. Turja,C.H . June, and
C.B. Thompson . 1990 . Thegenomic organization oftheCD28
gene . Implications for the regulation ofCD28 mRNA expres-
sion and heterogeneity.J . Immunol . 145:344 .
32 . Damle, N.K., L.V. Doyle, L.S . Grosmaire, andJ.A . Ledbetter.
1988 . Differential regulatory signals delivered by antibody
binding to the CD28 (Tp44) molecule during the activation
of human T lymphocytes.J. Immunol . 140:1753 .
33 . Damle,N.K ., J.A . Hansen, R.A . Good, and S . Gupta . 1981 .
Monoclonal antibody analysis of humanT lymphocyte sub-
populations exhibiting autologous mixedlymphocyte reaction .
Proc. Natl . Acad. Sci. USA . 78:5096.
34 . Lesslauer, W ., F . Koning, T . Ottenhoff, M. Giphart, E.
Goulmy, andJ.J . van Rood . 1986 . T90/44 (9.3 antigen) . A
cell surface molecule with afunction in humanT cell activa-
tion . Eur .J. Immunol . 16:1289.
35 . Williams, A.F., and A.N . Barclay. 1988 . The immunoglob-
ulin superfamily : domains for cell surface recognition . Annu.
Rev . Immunol. 6:381 .
36 . Alzari, P.M .,M.-B . Lascombe, andR.J . Poljak . 1988 . Three-
dimensional structure ofantibodies . Annu. Rev . Immunol.6:555 .
37 . Di Minno, G., P. Thiagagajan, B . Perussia, J . Martinez, S .
Shapiro, G. Trinchieri, and S . Murphy. 1983 . Exposure of
platelet fibrinogen-binding sitesby collagen, arachadonic acid,
and ADP: inhibition by a monoclonal antibody to the glyco-
protein IIb-IIIa complex . Blood. 61:140 .
38 . Hautanen,A., J . Gailit, D.M. Mann, andE. Ruoslahti . 1989 .
Effects ofmodifications of theRGD sequence and its context
on recognition of the fibronectin receptor. J . Biol. Chem .
264:1437 .
39 . Thiagarajan, P., and K.L . Kelley. 1988 . Exposure of binding
sites for vitronectin on platelets following stimulation .J. Biol.Chem . 263:3035.
40. Schnek, J.,WL. Maloy, J.E . Coligan, andD.H . Margulies .
1989 . Inhibitionof an allospecific T cell hybridoma by soluble
class I proteins and peptides : estimation of the affinity of a
T cell receptor for MHC. Cell . 56:47 .
41 . Recny,M.A ., E.A . Neidhardt, P.H . Sayre, TL . Ciardelli, and
569
￿
Linsley et al .
E.L . Reinherz . 1990 . Structural and functional characteriza-
tion of the CD2 immunoadhesion domain . J . Biol. Chem.
265 :8542 .
42 . Clayton, L.K ., M. Sieh, D . Pious, and E.L . Reinherz .
Identification of human CD4residues affecting class II MHC
versus HIV -1 gp120 binding. 1989 . Nature (Land.). 339:548 .